Cargando…

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)

SIMPLE SUMMARY: Depatux-M is an antibody-drug conjugate against activated EGFR. The efficacy and tolerability of the Depatux-M and temozolomide combination in recurrent glioblastoma patients were recently analyzed in the INTELLANCE-2/EORTC 1410 phase 2 trial. Despite the trial was negative, it showe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Padovan, Marta, Eoli, Marica, Pellerino, Alessia, Rizzato, Simona, Caserta, Claudia, Simonelli, Matteo, Michiara, Maria, Caccese, Mario, Anghileri, Elena, Cerretti, Giulia, Rudà, Roberta, Zagonel, Vittorina, Lombardi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8199759/ https://www.ncbi.nlm.nih.gov/pubmed/34204877 http://dx.doi.org/10.3390/cancers13112773

Ejemplares similares

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial
por: Lassman, Andrew B, et al.
Publicado: (2019)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial
por: Lassman, Andrew B, et al.
Publicado: (2022)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

The role of radiation therapy and systemic treatments in meningioma: The present and the future
por: Caccese, Mario, et al.
Publicado: (2023)

EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand
por: Hoogstrate, Youri, et al.
Publicado: (2019)

Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial
por: Narita, Yoshitaka, et al.
Publicado: (2021)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
por: Birzu, Cristina, et al.
Publicado: (2020)

Clinical Management of Diffuse Low-Grade Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
por: Goss, Glenwood D., et al.
Publicado: (2018)

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
por: van den Bent, Martin, et al.
Publicado: (2017)

A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin
por: Vize, Colin J., et al.
Publicado: (2023)

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2020)

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
por: Soffietti, Riccardo, et al.
Publicado: (2013)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
por: Di Ianni, Natalia, et al.
Publicado: (2021)

The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation
por: Tizianel, Irene, et al.
Publicado: (2022)

Serosurveillance for Japanese encephalitis, Akabane, and Aino viruses for Thoroughbred horses in Korea
por: Yang, Dong-Kun, et al.
Publicado: (2008)

Seroepidemiology of Aino Virus in Farmed and Free-Ranging Cervids in the Republic of Korea
por: Yeh, Jung-Yong, et al.
Publicado: (2021)

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
por: Olioso, Debora, et al.
Publicado: (2021)

PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care
por: Ruggiero, Elena, et al.
Publicado: (2022)

Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study
por: Caccese, Mario, et al.
Publicado: (2023)

Tumor volumes as a predictor of response to the anti-EGFR antibody drug conjugate depatuxizumab mafadotin
por: Gan, Hui K, et al.
Publicado: (2021)

ABCC3 Expressed by CD56(dim) CD16(+) NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy
por: Pellegatta, Serena, et al.
Publicado: (2019)

An Overview of Intracranial Ependymomas in Adults
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?
por: Preusser, Matthias
Publicado: (2019)

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Sero-survey on Aino, Akabane, Chuzan, bovine ephemeral fever and Japanese encephalitis virus of cattle and swine in Korea
por: Lim, Seong In, et al.
Publicado: (2007)

Detection and differentiation of Schmallenberg, Akabane and Aino viruses by one-step multiplex reverse-transcriptase quantitative PCR assay
por: Lee, Ji-Hye, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qv7v171nstc0kh0j0kblbsf20f